文献速递重症综合管理与镇静镇痛消化、代谢与肾脏急症

炎症生物标志物与危重症患者药物药代动力学的关系:范围综述

The relation between inflammatory biomarkers and drug pharmacokinetics in the critically ill patients: a scoping review.
PubMed 文献 · Crit Care · 2024-11-19
一句话结论炎症生物标志物可提示危重症患者药代动力学改变,个体化用药时需考虑炎症驱动的药代动力学变异。

本范围综述遵循PRISMA指南,检索Medline、Embase、Web of Science和Cochrane数据库(1946年1月至2023年11月),纳入危重症患者中炎症生物标志物与药代动力学参数或药物暴露相关的研究。共筛选4479条记录,31项研究符合纳入标准:吸收2项、分布7项、代谢17项、排泄6项。总体而言,仅有限药物有结果,多数研究仅关注ADME某一环节;炎症生物标志物水平升高可能根据药物是否经肝首过消除而增加或减少吸收,炎症与药物蛋白结合能力负相关、与脑脊液穿透正相关、与腹膜穿透负相关,多数药物代谢能力与炎症生物标志物负相关,炎症可导致药物清除减少(新生儿人群除外)。结论强调个体化用药时需考虑炎症驱动的药代动力学变异,同时研究限于特定药物且需进一步研究(包括药效学)。

要点

  • 共纳入31项研究:吸收2项、分布7项、代谢17项、排泄6项,多数仅关注ADME单一环节。
  • 炎症生物标志物水平升高可能根据药物是否经肝首过消除而增加或减少药物吸收。
  • 炎症与药物蛋白结合能力负相关,与脑脊液穿透正相关,与腹膜穿透负相关。
  • 多数药物代谢能力与炎症生物标志物负相关;炎症可导致药物清除减少,新生儿人群除外。
  • 作者认为个体化用药时需考虑炎症驱动的药代动力学变异,研究限于特定药物且需进一步研究(包括药效学)。

适用人群与场景

  • 危重症患者(纳入研究为危重症患者中 examining 炎症生物标志物、药代动力学参数或药物暴露的研究)

研究设计与关键结果

  • 范围综述遵循PRISMA指南,检索Medline、Embase、Web of Science和Cochrane数据库(1946年1月至2023年11月),共筛选4479条记录,31项研究符合纳入标准:吸收2项、分布7项、代谢17项、排泄6项。
  • 吸收:炎症生物标志物水平升高可能根据药物是否经肝首过消除而增加或减少药物吸收。
  • 分布:炎症与药物蛋白结合能力负相关,与脑脊液穿透正相关,与腹膜穿透负相关。
  • 代谢:多数药物代谢能力与炎症生物标志物负相关。
  • 排泄:炎症可导致药物清除减少,新生儿人群除外。
  • 总体而言,结果仅 available 于有限数量的药物,且多数研究仅关注ADME某一环节。

证据类型、等级与局限

  • 证据类型:范围综述(scoping review),遵循PRISMA指南。
  • 局限:研究限于特定药物且需进一步研究,包括药效学。

对床旁实践的改变

  • 作者认为炎症生物标志物可提供危重症患者药代动力学改变的有价值信息。
  • 作者认为个体化药物治疗时需考虑炎症驱动的药代动力学变异。
  • 作者指出研究限于特定药物且需进一步研究(包括药效学)。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: The level of inflammation alters drug pharmacokinetics (PK) in critically ill patients. This might compromise treatment efficacy. Understanding the specific effects of inflammation, measured by biomarkers, on drug absorption, distribution, metabolism, and excretion is might help in optimizing dosing strategies.

OBJECTIVES: This review investigates the relationship between inflammatory biomarkers and PK parameters absorption, distribution, metabolism and excretion (ADME) in critically ill patients, providing insight in the complexity of dosing drugs in critically ill patients.

METHOD: Following PRISMA guidelines, we conducted a comprehensive search of Medline, Embase, Web of Science, and Cochrane databases (January 1946-November 2023). Studies examining inflammatory biomarkers, PK parameters, or drug exposure in critically ill patients were included. Records were screened by title, abstract, and full text, with any discrepancies resolved through discussion or consultation with a third reviewer.

RESULTS: Of the 4479 records screened, 31 met our inclusion criteria: 2 on absorption, 7 on distribution, 17 on metabolism, and 6 on excretion. In general, results are only available for a limited number of drugs, and most studies are done only looking at one of the components of ADME. Higher levels of inflammatory biomarkers may increase or decrease drug absorption depending on whether the drug undergoes hepatic first-pass elimination. For drug distribution, inflammation is negatively correlated with drug protein binding capacity, positively correlated with cerebrospinal fluid penetration, and negatively correlated with peritoneal penetration. Metabolizing capacity of most drugs was inversely correlated with inflammatory biomarkers. Regarding excretion, inflammation can lead to reduced drug clearance, except in the neonatal population.

CONCLUSION: Inflammatory biomarkers can offer valuable information regarding altered PK in critically ill patients. Our findings emphasize the need to consider inflammation-driven PK variability when individualizing drug therapy in this setting, at the same time research is limited to certain drugs and needs further research, also including pharmacodynamics.

来源:Crit Care,查看原文。版权归原作者所有。

参考来源

  1. Li L, Zinger J, Sassen SDT, et al. The relation between inflammatory biomarkers and drug pharmacokinetics in the critically ill patients: a scoping review. Crit Care. 2024. PMID: 39563441. doi:10.1186/s13054-024-05150-4

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。